 | • レポートコード：MRC2304D144 • 出版社/出版日：Transparency Market Research / 2023年1月6日 • レポート形態：英文、PDF、167ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、マルチパラメーターin vitro心毒性検査の世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、アッセイ種類別（カルシウムトランジェントアッセイ、心臓マーカー検出、hERGアッセイ、マルチイオンチャネルアッセイ、その他）分析、エンドユーザー別（CRO、製薬＆バイオテクノロジー企業、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、その他）分析、競争状況などを収録しています。また、Creative Bioarray、Agilent Technologies, Inc.、Hemogenix Inc.、Merck KGaA、Molecular Devices, LLC.、Miltenyi Biotec、FUJIFILM Cellular Dynamics、Enzo Life Sciences, Inc.、Axol Bioscience Ltd.、emka TECHNOLOGIES、Eurofins Discovery、Stemina Biomarker Discovery, Inc.、Evotecなどの企業情報を掲載しています。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のマルチパラメーターin vitro心毒性検査市場規模：アッセイ種類別 - カルシウムトランジェントアッセイの市場規模 - 心臓マーカー検出の市場規模 - hERGアッセイの市場規模 - マルチイオンチャネルアッセイの市場規模 - その他アッセイ種類の市場規模 ・世界のマルチパラメーターin vitro心毒性検査市場規模：エンドユーザー別 - CROにおける市場規模 - 製薬＆バイオテクノロジー企業における市場規模 - その他エンドユーザーにおける市場規模 ・世界のマルチパラメーターin vitro心毒性検査市場規模：地域別 - 北米のマルチパラメーターin vitro心毒性検査市場規模 - ヨーロッパのマルチパラメーターin vitro心毒性検査市場規模 - アジア太平洋のマルチパラメーターin vitro心毒性検査市場規模 - その他地域のマルチパラメーターin vitro心毒性検査市場規模 ・競争状況 |
Multiparametric In-vitro Cardiotoxicity Testing Market – Scope of Report
TMR’s report on the global multiparametric in-vitro cardiotoxicity testing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global multiparametric in-vitro cardiotoxicity testing market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global multiparametric in-vitro cardiotoxicity testing market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the multiparametric in-vitro cardiotoxicity testing market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global multiparametric in-vitro cardiotoxicity testing market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global multiparametric in-vitro cardiotoxicity testing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global multiparametric in-vitro cardiotoxicity testing market.
The report delves into the competitive landscape of the global multiparametric in-vitro cardiotoxicity testing market. Key players operating in the global multiparametric in-vitro cardiotoxicity testing market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global multiparametric in-vitro cardiotoxicity testing market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market multiparametric in-vitro cardiotoxicity testing.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Multiparametric In-vitro Cardiotoxicity Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, 2017 – 2031
4.4.1. Market Revenue Projection (US$ Mn)
5. Key Insights
5.1. Key Industry Developments
5.2. Key Product/Brand Analysis
5.3. Emerging Technologies and Platforms for Cardiotoxicity Testing
5.4. Overview of In-vitro Cardiac Electrophysiology Platforms for Toxicology Assessment
5.5. Overview of Multiparametric In-vitro Toxicology Assessment
5.6. COVID-19 Impact Analysis
6. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, By Type of Assay
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast By Type of Assay, 2017 – 2031
6.3.1. Calcium Transient Assay
6.3.2. Cardiac Marker Detection
6.3.3. hERG Assay
6.3.4. Multi-ion Channel Assay
6.3.5. Others
6.4. Market Attractiveness By Type of Assay
7. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, By End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast By End-user, 2017 – 2031
7.3.1. Contract Research Organizations (CROs)
7.3.2. Pharmaceutical and Biotech Companies
7.3.3. Others
7.4. Market Attractiveness By End-user
8. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Rest of the World
8.3. Market Attractiveness By Country/Region
9. North America Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Type of Assay, 2017 – 2031
9.2.1. Calcium Transient Assay
9.2.2. Cardiac Marker Detection
9.2.3. hERG Assay
9.2.4. Multi-ion Channel Assay
9.2.5. Others
9.3. Market Value Forecast By End-user, 2017 – 2031
9.3.1. Contract Research Organizations (CROs)
9.3.2. Pharmaceutical and Biotech Companies
9.3.3. Others
9.4. Market Value Forecast By Country, 2017 – 2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type of Assay
9.5.2. By End-user
9.5.3. By Country
10. Europe Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Type of Assay, 2017 – 2031
10.2.1. Calcium Transient Assay
10.2.2. Cardiac Marker Detection
10.2.3. hERG Assay
10.2.4. Multi-ion Channel Assay
10.2.5. Others
10.3. Market Value Forecast By End-user, 2017 – 2031
10.3.1. Contract Research Organizations (CROs)
10.3.2. Pharmaceutical and Biotech Companies
10.3.3. Others
10.4. Market Value Forecast By Country/Sub-region, 2017 – 2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Type of Assay
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Type of Assay, 2017 – 2031
11.2.1. Calcium Transient Assay
11.2.2. Cardiac Marker Detection
11.2.3. hERG Assay
11.2.4. Multi-ion Channel Assay
11.2.5. Others
11.3. Market Value Forecast By End-user, 2017 – 2031
11.3.1. Contract Research Organizations (CROs)
11.3.2. Pharmaceutical and Biotech Companies
11.3.3. Others
11.4. Market Value Forecast By Country/Sub-region, 2017 – 2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Type of Assay
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type of Assay, 2017 – 2031
12.2.1. Calcium Transient Assay
12.2.2. Cardiac Marker Detection
12.2.3. hERG Assay
12.2.4. Multi-ion Channel Assay
12.2.5. Others
12.3. Market Value Forecast By End-user, 2017 – 2031
12.3.1. Contract Research Organizations (CROs)
12.3.2. Pharmaceutical and Biotech Companies
12.3.3. Others
12.4. Market Attractiveness Analysis
12.4.1. By Type of Assay
12.4.2. By End-user
13. Competition Landscape
13.1. Market Player – Competition Matrix (By Tier and Size of Companies)
13.2. Market Share Analysis By Company (2021)
13.3. Company Profiles
13.3.1. Creative Bioarray
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Product Portfolio
13.3.1.3. SWOT Analysis
13.3.1.4. Strategic Overview
13.3.2. Agilent Technologies, Inc.
13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Product Portfolio
13.3.2.3. SWOT Analysis
13.3.2.4. Strategic Overview
13.3.3. Hemogenix Inc.
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Product Portfolio
13.3.3.3. SWOT Analysis
13.3.3.4. Strategic Overview
13.3.4. Merck KGaA
13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.4.2. Product Portfolio
13.3.4.3. SWOT Analysis
13.3.4.4. Strategic Overview
13.3.5. Molecular Devices, LLC
13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.5.2. Product Portfolio
13.3.5.3. SWOT Analysis
13.3.5.4. Strategic Overview
13.3.6. Evotec
13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.6.2. Product Portfolio
13.3.6.3. SWOT Analysis
13.3.6.4. Strategic Overview
13.3.7. Miltenyi Biotec
13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.7.2. Product Portfolio
13.3.7.3. SWOT Analysis
13.3.7.4. Strategic Overview
13.3.8. FUJIFILM Cellular Dynamics
13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.8.2. Product Portfolio
13.3.8.3. SWOT Analysis
13.3.8.4. Strategic Overview
13.3.9. Enzo Life Sciences, Inc.
13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.9.2. Product Portfolio
13.3.9.3. SWOT Analysis
13.3.9.4. Strategic Overview
13.3.10. Axol Bioscience Ltd.
13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.10.2. Product Portfolio
13.3.10.3. SWOT Analysis
13.3.10.4. Strategic Overview
13.3.11. Stemina Biomarker Discovery, Inc.
13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.11.2. Product Portfolio
13.3.11.3. SWOT Analysis
13.3.11.4. Strategic Overview
13.3.12. emka TECHNOLOGIES
13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.12.2. Product Portfolio
13.3.12.3. SWOT Analysis
13.3.12.4. Strategic Overview
13.3.13. Eurofins Discovery
13.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.13.2. Product Portfolio
13.3.13.3. SWOT Analysis
13.3.13.4. Strategic Overview